Brief: Freeline Announces First Patient Dosed In The Phase 1/2 B-Lieve Dose-Confirmation Trial In Hemophilia B

Freeline Therapeutics Holdings

09/03/2022 12:49

March 9 (Reuters) - Freeline Therapeutics Holdings PLC  FRLN.O :
    * FREELINE ANNOUNCES FIRST PATIENT DOSED IN THE PHASE 1/2 B-LIEVE
DOSE-CONFIRMATION TRIAL IN HEMOPHILIA B

Source text for Eikon:  ID:nGNX2g5nC3 
Further company coverage:  FRLN.O 

 ((Reuters.Briefs@thomsonreuters.com;))